American Society of Clinical Oncology (ASCO) shared a post on LinkedIn:
“In the 1980s, federally funded researchers uncovered HER2’s role in aggressive breast cancer. That discovery sparked targeted therapies that transformed treatment: today >85% of women with HER2+ breast cancer survive 5+ years. It’s a breakthrough that continues to save lives. We can’t go back.
Tell your lawmakers to support cancer research funding.”
More posts featuring ASCO on OncoDaily.
Proceed to the video attached to the post.